Pall — RW Baird Industrial Conference 2012
19 slides from Pall's conference presentation, Nov 5, 2012
Slide 1: Building a Foundation for Sustainable Growth
Pall Corporation Better Lives. Better Planet.su Building a Foundation for Sustainable Growth Larry Kingsley President & CEO RW Baird Industrial Conference November 6, 2012
Slide 2: Forward-looking statements
“The matters discussed in this presentation contain “orwardlooking statements as defined in the Private Securities Ligation Reform Act of 1995. Forward- looking statements are those tht address aces, events or developments that the Company or management intends, expects, projects, believes or antpat
Slide 3: Our Filtration Solutions
Our Filtration Solutions «We filter valuable fluids “We protect valuable equipment and processes “We recover valuable solids (e.g. catalyst, bio material © cell recovery) Increased Improved Reduced Inrased Pall Differentiators ‘ceney = “purty” consumption “Yoid *Customer intima ey Pall filters fluid
Slide 4: Building a Foundation for Sustainable Growth
Building a Foundation for Sustainable Growth Vision =To be the premier global provider of filtration, separation and purification science enabling technologies in chosen high-growth end markets Innovation leader Disciplined in how we execute Driven by end customers and the channel Goals =Technology
Slide 5: Great Business Model Fundamentals
Great Business Model Fundamentals = Attractive end markets = Strong moat = ~ 80% of sales from consumables = Non-discretionary products = Applications expertise = Global sales channel « Manufacturing scalability ForteBio's Octet® RED384 for high-throughput, real-time analysis of biomolecular interac
Slide 6: Our Diversity is a Strength
BloPharmaceuticals Medical Food & Beverage Bologicals (Vaccines & —Transtision Beer Pia) Medine Wine & Spits Biotech Drugs cel Theapy Neonates Classic Pharmaceuticals * Veterinary Beverages abortory Toole Hospital infection Food & Da LaberyTob tt Food & Daty Peet Hea Sono agnostics + Ciitical Care *
Slide 7: Product quality, productivity & innovation
= Product quality, productivity & innovation = Global demographic changes = Water & energy management = Environmental & regulatory requirements = Emerging & mutating pathogens Pat Corporaton
Slide 8: People, Process & Technology
=) People, Process & Technology ail Executing a priority agenda around people, processes and technology: “Building executive team =Deploying resources into growth markets and regions “Implemented new executive and sales compensation plans Launched global ERP system Increasing the velocity of product
Slide 9: Vision for Technology
Vision for Technology: “Product Development Engine” that quickly and effectively cranks out robust, differentiated, quality products that meet our customers’ needs and contribute significantly to our growth and margin with minimal capital requirements = Develop and launch innovative media with categ
Slide 10: Sales by Segment, Sales by Region
Sales by Segment Sales by Region 08, Industrial Europe Americas Consumables Consumables $1,023 $840 $1,133 47.0% $1,159 46.4% +8.4% +5.5% Life Sciences i Industrial Asia Systems gous ae ‘- $259 47.0% +10.5% 414.8% Total Sales: $2,672 (+7.2% oranges outside plo carts sen sals change excdng FX combs s
Slide 11: In this challenging economic environment we must
In this challenging economic environment we must: = Invest in innovation = Improve/reduce SG&A on cost structure " Pal Corporation
Slide 12: Q1 Preliminary Analysis
Q1 Preliminary Analysis Q1 Sales & Orders Orders down ~4% excluding FX Sales about flat excluding FX =FX headwind of 3.5 — 4.0% Tailwinds Headwinds =Biopharm projects *MicroE: End markets =Achieving cost savings ="M&E: End markets & destocking =Process: Project delays “Asia: China construction-relat
Slide 13: Headwinds persist
+ Headwinds persist: = Global economy - FX = Fiscal uncertainty + Fiscal Qt isa challenging comparable due to FX 7-40 cent headwind + Re-assessing full year outlook; current bias towards low end of earnings guidance 8
Slide 14: FY 2013 Business Outlook
FY 2013 Business Outlook Previous Expectation”) wt Highlights: *MicroE recovery »Process weakness in Europe *Broad-based strength in Asia Current Expectation Americas Europe Asia BioPharm Medical MicroE Process ‘Aerospace FaB Highlights: *MicroE recovery delayed Industrial weakness generally *Life S
Slide 15: Our Vision Forward: Industry Best in Class
Our Vision Forward: Industry Best in Class Top Quartile ROC* Performance Reduce ) Cost to Serve @ Organic Growth at 2X Global GDP Industry @ * Differentiated innovation Leading Indust «= Share of customer spend fi) ry + Marketshare gain @ ‘ae = New product development ality + Flow-through of 30-40%
Slide 16: Pall Corporation Better Lives. Better Planet.
Pall Corporation Better Lives. Better Planet.su | a2 GREENER FUTURE.. www.pall.com/green (©2012 Pal Corporation
Slide 17: Appendix: Life Sciences & Industrial Sales
Appendix: Life Sciences & Industrial Sales Reconciliation of Non-GAAP Financial Measures Full Year | Full Year FY12 FY12 Estimated | Estimate % Change FullYear | impactof | Excluding | Full Year| Excluding FY12 FX FX FY14 FX Life Sciences: Consumables Sales |$ 1.1324) $ (15.0) |$ 1,147.4) $ 1,0724 7
Slide 18: Appendix: Life Sciences & Industrial Sales by Market
Appendix: Life Sciences & Industrial Sales by Market Reconciliation of Non-GAAP Financial Measures Full Year FY12 Estimated | Estimate Full Year | Impact of | Excluding | Full Year FY12 EX FX FY14 Life Sciences Sales BioPharmaceuticals |$ 8169) $ (96) |$ 8265) $ 7380 12.0% Medical 1952 (28) 198.0 20
Slide 19: Appendix: Sales by Region
Appendix: Sales by Region Reconciliation of Non-GAAP Financial Measures Full Year Fy12 Full Year FY12 Estimated | Estimate Change FulYear | Impact of | Exctuding | FullYear | Excluding FY12 EX FY14 EX Life Science Sales: Americas S$ 3848 $ (24 S$ 3872| $ 3453 12.1% Europe 6064 (188) 625.2 6055 3.2%